David A. Siegel Arrowhead Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 21,734 shares of ARWR stock, worth $896,744. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,734

Previous 391,800 94.45%

Holding current value

$896,744

Previous $6.19 Million 87.9%

% of portfolio

0.0%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$14.71 - $34.49 $5.44 Million - $12.8 Million	-370,066 Reduced 94.45%	21,734 $749,000
Q2 2025 Aug 14, 2025	SELL	$9.99 - $16.97 $3.32 Million - $5.63 Million	-332,000 Reduced 45.87%	391,800 $6.19 Million
Q1 2025 May 15, 2025	BUY	$12.74 - $21.53 $3.73 Million - $6.31 Million	293,100 Added 68.05%	723,800 $9.22 Million
Q4 2024 Feb 14, 2025	BUY	$17.7 - $26.34 $5.85 Million - $8.71 Million	330,700 Added 330.7%	430,700 $8.1 Million
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $40,656 - $62,034	-2,100 Reduced 2.06%	100,000 $1.94 Million

Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $1.38 Million - $1.79 Million	63,300 Added 163.14%	102,100 $2.65 Million
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $1.05 Million - $1.53 Million	-38,700 Reduced 49.94%	38,800 $1.11 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $1.39 Million - $2.03 Million	-65,400 Reduced 45.77%	77,500 $2.37 Million
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $2.38 Million - $3.28 Million	91,000 Added 175.34%	142,900 $3.84 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $500,684 - $823,462	19,900 Added 62.19%	51,900 $1.85 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $757,760 - $1.23 Million	32,000 New	32,000 $812,000
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $1.18 Million - $1.67 Million	-20,300 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $1.96 Million - $2.85 Million	-33,500 Reduced 62.27%	20,300 $1.27 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $2.86 Million - $4.15 Million	-46,000 Reduced 46.09%	53,800 $4.46 Million
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $2.8 Million - $4.13 Million	45,600 Added 84.13%	99,800 $6.62 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $6.18 Million - $12 Million	-141,100 Reduced 72.25%	54,200 $4.16 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $15.5 Million - $24 Million	-467,800 Reduced 70.55%	195,300 $8.41 Million
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $982,112 - $1.63 Million	37,600 Added 6.01%	663,100 $28.6 Million
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $9.69 Million - $29.7 Million	471,300 Added 305.64%	625,500 $18 Million
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $1.41 Million - $3.67 Million	50,200 Added 48.27%	154,200 $9.78 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $3.63 Million - $4.82 Million	-138,400 Reduced 57.1%	104,000 $2.93 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $2.92 Million - $4.83 Million	167,700 Added 224.5%	242,400 $6.42 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $900,135 - $1.51 Million	74,700 New	74,700 $1.37 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $214,800 - $394,000	-20,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.0 - $20.3 $280,000 - $406,000	20,000 New	20,000 $383,000

Others Institutions Holding ARWR

# of Institutions

339

Shares Held

103M

Call Options Held

953K

Put Options Held

263K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $4.37B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account